Prof. Garry Duffy
NUI Galway, Centre for Research in Medical Devices
Garry Duffy is a Professor in Anatomy and Regenerative Therapies within the School of Medicine at the National University of Ireland Galway. He has a keen interest in developing minimally-invasive surgical devices to enable the future translation of biomaterial based cell and drug therapy products.
Prof. Richard Oreffo
University of Southampton
Richard Oreffo is the chair of Musculoskeletal Science and is co-founder and Director of the Centre for Human Development, Stem Cells and Regeneration at the University of Southampton .Richard's particular interests lie in the application of bone stem cells and regenerative medicine strategies for the repair and regeneration of damaged skeletal tissue.
Prof. Andriana Margariti
Queen's University Belfast
Prof. Margariti has main expertise lies in stem cell biology, with particular emphasis on cell reprogramming, chromatin remodelling, cell signalling and endothelial cell biology. Her research demonstrates the therapeutic potential of “re-born” reprogrammed endothelial cells have transforming consequences for regenerative and personalised medicine.
CATAPULT: Cell and Gene Therapy Manufacturing
The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies. They are a team of experts covering all aspects of advanced therapies. Applying their unique capabilities and assets, they collaborate with academia, industry, and health care providers to develop new technology and innovation. Their outputs leverage research, transform barriers into industrial advantage and attract investment for their collaborators. They help people acquire new skills, organisations establish new capabilities and policy makers develop new perspectives.
MicrofluidX is a company who take on the challenges of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy. Its automated, closed technology allows biologists to easily carry out process development by running dozens of cell culture conditions in parallel with extreme process control, and to scale up seamlessly up to several billion cells for manufacturing at a fraction of the current costs. Four members from MicrofluidX will be joining us at FIRM to run a workshop on bioprocessing.